Searching for antiviral drugs for human papillomaviruses

Antiviral Therapy

Volumn 5, Issue 4, 2000, Pages 229-242

  Underwood, M R ^a   Shewchuk, L M ^a   Hassell, A M ^a   Phelps, W C ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIVIRAL ACTIVITY; CONDYLOMA; DISEASE ASSOCIATION; EPITHELIUM TUMOR; GENE EXPRESSION; GENITAL TRACT CANCER; HERPES; HERPES SIMPLEX VIRUS; HIGH RISK POPULATION; HUMAN; MOUTH MUCOSA; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; REVIEW; SEXUALLY TRANSMITTED DISEASE; VIRUS GENE; VIRUS REPLICATION; WART VIRUS;

ANTIVIRAL AGENTS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS;

EID: 0034545641     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Epidemiology of genital human papillomavirus infection
2. Estimates of incidence and prevalence of sexually transmitted diseases in the United States
3. Natural history of cervicovaginal papillomavirus infection in young women
4. Natural history of genital human papillomavirus infections
5. History of genital warts in 10,838 women 20 to 29 years of age from the general population
6. Cancer causes revisited: Human papillomavirus and cervical neoplasia
7. Pernicious papillomavirus infection
8. Epidemiology and biology of cervical cancer
9. Controversies in the management of low-grade cervical intraepithelial neoplasia
10. Papillomaviruses in human cancers
11. Human papillomavirus life cycle: Active and latent phases
12. Contemporary theories of cervical carcinogenesis: The virus, the host, and the stem cell
13. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
14. Human papillomavirus and associated malignancies
15. Epidemiology of HPV infections
16. Progesterone and glucocorticoid response elements occur in the long control regions of several human papillomaviruses involved in anogenital neoplasia
17. Recurrent respiratory papillomatosis: Clinical overview and management principles
18. Mechanism for human papillomavirus transmission at birth
19. Low risk of perinatal transmission of human papillomavirus: Results from a prospective cohort study
20. On warts
21. Management strategies
22. Interferon treatment of anogenital human papillomavirus-related diseases
23. In vitro and animal models for antiviral therapy in papillomavirus infections
24. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata
25. Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse
26. Human papillomaviruses target differentiating epithelia for virion production and malignant conversion
27. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral life cycle
28. Rolling-circle replication of a high-copy BPV-1 plasmid
29. Differentiation-induced changes in promoter usage for transcripts encoding the human papillomavirus type 31 replication protein E1
30. In vitro synthesis of oncogenic human papillomavirus requires episomal genomes for differentiation-dependent late expression
31. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic
32. Interactions of HPV E6 and E7 with tumour suppressor gene products
33. Mechanism of HPV E6 proteins in cellular transformation
34. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
35. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300
36. Binding of human virus oncoproteins to hDlg/SAP97, a mammalian homolog of the Drosophila discs large tumor suppressor protein
37. Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein
38. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein
39. ERC-55, a binding protein for the papilloma virus E6 oncoprotein, specifically interacts with vitamin D receptor among nuclear receptors
40. The bovine papillomavirus E6 oncoprotein interacts with paxillin and disrupts the actin cytoskeleton
41. New HPV E6 binding proteins: Dangerous liaisons?
42. Telomerase activation by the E6 gene product of human papillomavirus type 16
43. Inhibition of Bak-induced apoptosis by HPV-18 E6
44. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity
45. The human papillomavirus-E7 protein as a transforming and transactivating factor
46. Analysis of transactivation by human papillomavirus type 16 E7 and adenovirus 12S E1A suggests a common mechanism
47. E2F: A link between the Rb tumor suppressor protein and viral oncoproteins
48. Homologous sequences in adenovirus E1A and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins
49. Association of the human papillomavirus type 16 E7 protein with the S-phase specific E2F-cyclin A complex
50. Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107
51. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV16 E7 oncoprotein
52. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2
53. Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein
54. The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors
55. HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation
56. The viral oncoproteins Ad5 E1A, HPV16 E7 and SV40Tag bind a common region of the TBP-associated factor-110
57. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26S proteasome
58. A novel human DNAJ protein, hTid-1, a homolog of the Drosophila tumor suppressor protein Tid56, can interact with the human papillomavirus type 16 E7 oncoprotein
59. Discovering high-affinity ligands for proteins
60. Anatomy of hot spots in protein interfaces
61. Covalent modification as a strategy to block protein-protein interactions with small-molecule drugs
62. Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18
63. Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames
64. Recruitment and loading of the E1 intiator protein: An ATP-dependent process catalysed by a transcription factor
65. Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type-11 origin
66. cis-Acting components of human papillomavirus (HPV) DNA replication: Linker substitution analysis of the HPV type 11 origin
67. Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins
68. Transient replication of human papillomavirus DNAs
69. The functions of human papillomavirus type 11 E1, E2, and E2C protein in cell-free DNA replication
70. Separate domains in the E1 and E2 proteins serve architectural and productive roles for cooperative DNA binding
71. Papillomavirus DNA replication
72. Identification of a 68 kilodalton nuclear ATP-binding phosphoprotein encoded by bovine papillomavirus type 1
73. The E1 protein of bovine papillomavirus 1 is an ATP-dependent DNA helicase
74. DNA-binding domain of bovine papillomavirus type 1 E1 helicase: Structural and functional aspects
75. Bovine papilloma virus (BPV)-encoded E1 protein contains multiple activities required for BPV DNA replication
76. Characterization of human papillomavirus type 11 E1 and E2 proteins expressed in insect cells
77. E1 protein of human papillomavirus is a DNA helicase/ATPase
78. A common function for polyoma virus large-T and papillomavirus E1 proteins
79. Bovine papillomavirus type 1 E1 and simian virus 40 large T antigen share regions of sequence similarity required for multiple functions
80. A common set of conserved motifs in a vast variety of putative nucleic acid-dependent ATPases including MCM proteins involved in the initiation of eukaryotic DNA replication
81. Inhibition of herpes simplex virus replication by a 2-amino thiazole via interations with the helicase component of the UL5-UL8-UL52 complex
82. A fluorescence-based assay for monitoring helicase activity
83. A helicase assay based on the displacement of fluorescent, nucleic acid-binding ligands
84. The papillomavirus E1 protein forms a DNA-dependent hexameric complex with ATPase and DNA helicase activities
85. Replication-associated activities of purfied human papillomavirus type 11 E1 helicase
86. Cell-free replication of the human papillomavirus DNA with homologous viral E1 and E2 proteins and human cell extracts
87. Human Hsp70 and Hsp40 chaperone proteins facilitate human papillomavirus-11 E1 protein binding to the origin and stimulate cell-free DNA replication
88. The E1 helicase of human papillomavirus type 11 binds to the origin of replication with low sequence specificity
89. Bovine papillomavirus type 1 DNA replication: The transcriptional activator E2 acts in vitro as a specificity factor
90. A high capacity assay for inhibitors of human papillomavirus DNA replication
91. A novel drug screening assay for papillomavirus specific antiviral activity
92. Properties of a non-tumorigenic human cervical keratinocyte cell line
93. Amplification of human papillomavirus genomes in vitro is dependent on epithelial differentiation
94. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implication for cervical cancer
95. Molecular analysis of episomal human papillomavirus type 16 DNA in a cervical carcinoma cell line
96. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA
97. Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line
98. Human papillomavirus type 31 oncoproteins E6 and E7 are required for the maintenance of episomes during the viral life cycle in normal human keratinocytes
99. The papillomavirus E2 regulatory proteins
100. A fluorescence anisotropy study of DNA binding by HPV-11 E2C Protein: A hierarchy of E2-binding sites
101. Specific recognition nucleotides and their DNA context determine the affinity of E2 protein for 17 binding sites in the BPV-1 genome
102. DNA binding and bending by the human papillomavirus type 16 E2 protein: Recognition of an extended binding site
103. Section III
104. The acidic transcriptional activation Domains of VP16 and p53 bind the cellular replication protein-A and stimulate in vitro BPV-1 DNA replication
105. Isolation of a BPV1 E2 transactivation domain binding factor required for both transcriptional activation and DNA replication
106. Direct interaction between Sp1 and the BPV enhacer E2 protein mediates synergistic activation of transcription
107. The bovine papillomavirus 1 E2 protein contains two activation domains: One that interacts with TBP and another that functions after TBP binding
108. Bovine papillomavirus type 1 E2 transcriptional regulators directly bind two cellular transcription factors, TFIID and TFIIB
109. Mapping and characterization of the interaction domains of human papillomavirus type 16 E1 and E2 proteins
110. The transactivation and DNA binding domains of the BPV-1 E2 protein have different roles in co-operative origin binding with the E1 protein
111. Mutations in the human papillomavirus type 16 E2 protein identify a region of the protein involved in binding to E1 protein
112. Structure of the intact transactivation domain of the human papillomavirus E2 protein
113. Crystal structure of the human papillomavirus type 18 E2 activation domain
114. E2 polypeptides encoded by bovine papillomavirus type 1 form dimers through the common carboxy-terminal domain: Transactivation is mediated by the conserved amino terminal domain
115. Amino acids necessary for DNA contact and dimerization imply novel motifs in the papillomavirus E2 transactivator
116. Crystal structure at 1.7 Å of the bovine papillomavirus-1 E2 DNA-binding domain bound to its DNA target
117. Solution structure of the DNA-binding domain of a human papillomavirus E2 protein: Evidence for flexible DNA-binding regions
118. Subunit rearrangement accompanies sequence-specific DNA binding by the bovine papillomavirus-1 E2 protein
119. Crystal structure of the DNA binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA
120. Phosphorylation sites of the E2 transcriptional regulatory proteins of bovine papillomavirus type 1
121. Segregation of viral plasmids depends on tethering to chromosomes and is regulated by phosphorylation
122. Protein-protein interactions as therapeutic targets for cancer
123. In vitro evaluation of phosphorothioate oligonucleotides targeted to the E2 mRNA of papillomavirus: Potential treatment for genital warts
124. Inhibition of the bovine papillomavirus E2 protein activity by peptide nucleic acid
125. A fifteen amino acid peptide inhibits human papillomavirus E1-E2 interaction and human papillomavirus DNA replication in vitro
126. NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein
127. HPV Infection: Future prospects
128. Vaccination with yeast-expressed cottontail rabbit (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation
129. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas
130. Virus-like particles of bovine papillomavirus type-4 in prophylactic and therapeutic immunization
131. Human papillomavirus vaccines